Overview
BioXcel Q3 2025 revenue and net income miss analyst expectations
Company plans sNDA submission for BXCL501 in Q1 2026
BioXcel advances late-stage clinical trials for BXCL501
Outlook
BioXcel plans to submit an sNDA for IGALMI® in Q1 2026
Company preparing for TRANQUILITY In-Care Phase 3 Trial
BioXcel sees U.S. at-home agitation market at 57-77 mln episodes annually
Result Drivers
R&D EXPENSES - Increased due to heightened clinical trial activity, particularly related to the SERENITY at-home Phase 3 studies
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $98,000 | $216,000 (5 Analysts) |
Q3 Net Income | Miss | -$30.91 mln | -$14.10 mln (5 Analysts) |
Q3 Basic EPS | Miss | -$2.18 | -$1.24 (5 Analysts) |
Q3 Operating Income | Miss | -$14.23 mln | -$11.40 mln (4 Analysts) |
Q3 Operating Expenses | $14.33 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $12.00, about 83.2% above its November 11 closing price of $2.02
Press Release: ID:nGNX9M37cN
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)